Hjem › Virusinfeksjoner › Maryland
Kliniske studier for Virusinfeksjoner i Maryland
14 studier for Virusinfeksjoner søker deltakere på steder i Maryland.
Byer i Maryland
Offisiell studietekst (engelsk)
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- Research Site, Annapolis
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05624450Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 18 til 120 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT00006518The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 2 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT01011712A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- Centennial Medical Group, Columbia
- Jadestone Clinical Research, Silver Spring
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06679140A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
- Johns Hopkins Hospital, Baltimore
- Jadestone Clinical Research, Silver Spring
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07013474Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 50 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07706686Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
- University of Maryland, Baltimore
RekruttererFase 2
Alder 18 til 65 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT07654283Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
- National Institutes of Health Clinical Center, Bethesda
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 50 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06863142Viral Infections in Healthy and Immunocompromised Hosts
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
6 Months – 120 Years · Alle kjønn · Oppdatert 14. sep. 2026 · NCT01306084Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
2 Months – 115 Years · Alle kjønn · Oppdatert 10. sep. 2026 · NCT04419870Genetic Studies of Chronic Active Epstein-Barr Disease
- National Institutes of Health Clinical Center, Bethesda
RekruttererObservasjonsstudie
Alder 1 til 120 · Alle kjønn · Oppdatert 28. jul. 2026 · NCT00032513Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)
- Johns Hopkins, Baltimore
RekruttererFase 1/2
1 Month – 79 Years · Alle kjønn · Oppdatert 15. apr. 2026 · NCT04197596Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
- Johns Hopkins University, Baltimore
- National Institutes of Health (NIH), Bethesda
RekruttererFase 1
3 Months – 80 Years · Alle kjønn · Oppdatert 26. jan. 2026 · NCT04691622Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
- All Natural Medicine Clinic, LLC, Rockville
RekruttererFase 1/2
Alle aldre · Alle kjønn · Oppdatert 19. feb. 2025 · NCT04790240Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.